• 1
    Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973-989.
  • 2
    Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986; 314: 1600-1606.
  • 3
    Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987; 5: 21-26.
  • 4
    Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol. 1998; 16: 3641-3648.
  • 5
    Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998; 16: 658-663.
  • 6
    Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008; 98: 415-420.
  • 7
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790.
  • 8
    Kim MS, Cho WH, Song WS, Lee SY, Jeon DG. Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res. 2007; 463: 157-165.
  • 9
    Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994; 12: 423-431.
  • 10
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 76-84.
  • 11
    Abdel-Dayem HM, Scott AM, Macapinlac HA. Thallium-201 chloride: a tumor imaging agent. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol 1. 3rd ed. Edinburgh: Churchill Livingstone; 2004: 71-81.
  • 12
    Hisada K, Tonami N, Miyamae T, et al. Clinical evaluation of tumor imaging with 201 TI chloride. Radiology. 1978; 129: 497-500.
  • 13
    Schoder H, Kushner BH, Yeung H. PET imaging in pediatric oncology. In: Ell PJ, Gambhir SS, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Vol 1. 3rd ed. Edinburgh: Churchill Livingstone; 2004: 305-319.
  • 14
    Imbriaco M, Yeh SD, Yeung H, et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer. 1997; 80: 1507-1512.
  • 15
    Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977; 101: 14-18.
  • 16
    Harrell F. Regression Modeling Strategies. New York: Springer-Verlag New York, Inc; 2001.
  • 17
    Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-2011.
  • 18
    Rosen G, Loren GJ, Brien EW, et al. Serial thallium-201 scintigraphy in osteosarcoma. Correlation with tumor necrosis after preoperative chemotherapy. Clin Orthop Relat Res. 1993;( 293): 302-306.
  • 19
    Kunisada T, Ozaki T, Kawai A, Sugihara S, Taguchi K, Inoue H. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy: angiography compared with thallium-201 scintigraphy. Cancer. 1999; 86: 949-956.
  • 20
    Lin J, Leung WT, Ho SK, et al. Quantitative evaluation of thallium-201 uptake in predicting chemotherapeutic response of osteosarcoma. Eur J Nucl Med. 1995; 22: 553-555.
  • 21
    Ohtomo K, Terui S, Yokoyama R, et al. Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med. 1996; 37: 1444-1448.
  • 22
    Ilhan IE, Vural G, Berberoglu S, Kapucuoglu N, Cila A, Eke S. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response. Pediatr Hematol Oncol. 2005; 22: 153-162.
  • 23
    Kaste SC, Billips C, Tan M, et al. Thallium bone imaging as an indicator of response and outcome in nonmetastatic primary extremity osteosarcoma. Pediatr Radiol. 2001; 31: 251-256.
  • 24
    Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001; 91: 2230-2237.
  • 25
    Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003; 228: 271-278.
  • 26
    Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999; 40: 1637-1643.
  • 27
    Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000; 25: 874-881.
  • 28
    Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer. 2002; 94: 3277-3284.
  • 29
    Hawkins DS, Conrad EU 3rd, Butrynski JE, Schuetze SM, Eary JF. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009; 115: 3519-3525.